TOPOGRAPHY-GUIDED LASER SURGERY

Indications, scope, and challenges.

BY SIMON P. HOLLAND, MB, FRCSC, FRCS, MRCP, AND DAVID T. C. LIN, MD, FRCSC

The greatest value of topography-guided laser surgery is for treating highly aberrated corneas that are difficult to image with other systems.1,2 The procedure regularizes the corneal surface to improve refractive outcomes. Any change in shape will induce a refractive effect requiring complex and individually derived treatment planning.

Topography-guided laser surgery is effective for improving symptoms (eg, glare, halos, distorted vision), UCVA, and BCVA in eyes with a wide range of irregular astigmatism.3 Indications include complications of previous laser eye surgery,4 asymmetrical astigmatism, corneal scarring after keratoplasty, and—when the procedure is combined with corneal collagen cross-linking (CXL)—ectatic conditions such as post-LASIK ectasia and keratoconus.5 Topography-guided laser systems are also used to treat normal eyes (ie, with good BCVA and low aberrations), although this has not been our practice.6,7

Several systems are available internationally, but at present, only the Wavelight Allegretto T-CAT (Alcon) and the Navex Quest EC-5000 (Nidek) are approved in the United States (this article includes discussion of off-label indications). We started working with the Wavelight platform in 2003 and more recently began using the Schwind Amaris 1050 SmartSurface (Schwind Eye-Tech Solutions).

METHODS

All topography-guided laser platforms require a linked imaging system from which the treatment is derived and modified by customization. We developed a topography neutralization technique to compensate for the shape-induced refractive changes.8

Surgeons can perform both PRK and LASIK with topography-guided platforms. Using the Wavelight and the Schwind systems, we have performed more than 1,500 cases of transepithelial PRK. Many patients are referred to us for complications of previous refractive surgery that lifting the flap may exacerbate. Low pachymetry readings frequently limit how much further treatment is possible on the residual stromal bed. We administer mitomycin C 0.02% upon the completion of topography-guided PRK (TG-PRK) to minimize haze. We closely monitor patients during the first postoperative week for satisfactory epithelialization, because a delay may cause corneal scarring and increase the risk of herpetic keratitis.

PROCEDURES

Keratoconus

Combining TG-PRK with CXL for the treatment of keratoconus can achieve satisfactory results. We used the Wavelight system to perform the combined procedure on 266 eyes. At 1 year, 133 (50%) had a distance UCVA of 20/40 or better. Seventy eyes (26%) had experienced an improvement in distance BCVA of 2 lines or more, whereas 17 (6%) had lost 2 lines or more. Complications included delayed epithelial healing with subsequent haze that was sufficient in three eyes to reduce BCVA by more than

![Figure 1. Combined TG-PRK and CXL for keratoconus. Different treatment axis from refractive axis after topographical neutralization.](image-url)
2 lines, three eyes required corneal transplantation, and two eyes developed herpetic keratitis. In our experience with the Wavelight platform, the treatment axis may be different from the refractive axis after topographic neutralization (Figure 1).

We have performed the combined procedure using the Schwind system on 133 eyes. One year postoperatively, 71 eyes (63%) had a distance UCVA of 20/40 or better, 29 (22%) had experienced an improvement in distance BCVA of 2 lines or more, and four (3%) had lost 2 lines of distance BCVA.9

**Post-LASIK Ectasia**

Combining TG-PRK with CXL is an effective treatment for post-LASIK ectasia. Surgery is often possible despite a low pachymetry reading, because treatment is rarely deep enough to reach the flap interface. In our hands, the combined procedure using either laser platform achieved a distance UCVA of 20/40 or better in more than 50% of eyes (n = 29). Distance BCVA improved or did not change in 77% and 91% of eyes treated with the Wavelight and Schwind system, respectively. Our early outcomes show satisfactory safety and efficacy results that are consistent with those achieved by other surgeons using the same or similar techniques (Figure 2).9

---

**Figure 2. TG-PRK for post-LASIK ectasia.**

**Figure 3. Post-RK TG-PRK.**

**Figure 4. TG-PRK for LASIK flap trauma.**

**Figure 5. TG-PRK for postkeratoplasty astigmatism.**

---

“**We closely monitor patients during the first postoperative week for satisfactory epithelialization.**”
Complications After Refractive Surgery

TG-PRK is an option for treating eyes with poor distance BCVA and irregular astigmatism after refractive surgery, including radial keratotomy (RK). The procedure can be used to address small optical zones, decentered ablations, corneal scarring, buttonhole flaps, and central islands. We use the approach in symptomatic patients with irregular astigmatism who have sufficient corneal thickness and realistic expectations, provided that image capture is successful.

Of the 12 post-RK patients we treated using the Schwind system, half achieved a distance UCVA of 20/40 or better, and 83% (n = 10) had a distance BCVA that improved or remained unchanged (Figure 3).10 The procedure can also effectively address other causes of severe irregular astigmatism such as LASIK flap trauma (Figure 4).

Postkeratoplasty Astigmatism

TG-PRK has been found effective for the treatment of extreme and/or irregular astigmatism after corneal transplantation (Figure 5). One year after TG-PRK on 38 eyes, 14 (37%) had a distance UCVA better than 20/40, with 12 (32%) gaining 2 or more lines of vision.11

CONCLUSION

Topography-guided laser surgery may be an effective option for irregular astigmatism in a wide range of conditions that were previously difficult to treat. Longer-term results are needed to establish the procedure’s safety and stability beyond 5 years. In our experience, however, the difference is less with the Schwind Amaris 1050 SmartSurface, and there is a limited or filtered option. Newer technology and FDA approval of CXL with the KXL System (Avedro) are widening the scope of treatment.

Longer-term results are needed to establish the procedure’s safety and stability beyond 5 years.

References


Simon P. Holland, MB, FRCS, FRCS, MRCP
- Pacific Laser Eye Centre, Vancouver, British Columbia, Canada
- (604) 736-2625; simon_holland@telus.net
- financial disclosure: speaker for Alcon, Allergan, Clarion

David T. C. Lin, MD, FRCS
- Pacific Laser Eye Centre, Vancouver, British Columbia, Canada
- (604) 736-2625; tclin@shaw.ca
- financial disclosure: speaker for Allergan, Schwind Eye-Tech Solutions